“RNAi & Antisense” — FilingIndex Search

Filter

5 of 3,901

Sort

RPRXRoyalty Pharma plc⚡

Healthcare · Pharmaceuticals

$24.32B-1.8%

P/E 17.9·P/S 10.0·Mgn 55.7%·ROE 7.9%·FCF —

—

13D

BBIOBridgeBio Pharma, Inc.

Healthcare · Pharmaceuticals

$13.08B+3.4%

P/E —·P/S 22.6·Mgn -125.9%·ROE —·FCF -3.4%

F 2

13DRed 8-K

WVEWave Life Sciences Ltd.

Healthcare · Pharmaceuticals

$1.13B+2.3%

P/E —·P/S 15.7·Mgn -255.7%·ROE -39.4%·FCF -16.7%

—

13D

BNTCBenitec Biopharma Inc.

Healthcare · Pharmaceuticals

$384M+5.3%

P/E —·P/S —·Mgn —·ROE -39.0%·FCF —

—

Red 8-K

CDXSCODEXIS, INC.

Materials · Chemicals

$218M-3.0%

P/E —·P/S 2.8·Mgn -41.0%·ROE -87.0%·FCF -10.9%

F 4

Red 8-K

Filings · filterAll 10-K 10-Q 8-K S-1 DEF 14A SC 13D

Filings

40 shown

BPREBluerock Private Real Estate Fund

DEF 14A

Proxy statement — executive pay, board nominees, and shareholder votes.

Jun 30, 2026·18h ago

CYCUWCycurion, Inc.

DEF 14A

Proxy statement — executive pay, board nominees, and shareholder votes.

Companies above the $50M market cap · $1 pricefloor; SPAC/shells hidden by default. Fundamentals & prices via Polygon · signals from SEC EDGAR — verify on SEC.gov. Filings current to Jun 30 · prices to Jun 30.